Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis

Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials

Lupin receives FDA approval for biosimilar Armlupeg

Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

Feinstein Institutes awarded $3.37 million grant to boost first responder mental health

The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas

GE HealthCare launches game-changing StarGuide GX for precision nuclear medicine

StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics

Gan & Lee Pharma launches Phase 3 trial of once-monthly weight-loss jab

InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China

Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders

Medanta launches 550-bed super speciality hospital in Noida

The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs

Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients

The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio

GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma

GV20 received an upfront payment and is eligible for additional milestone payments